Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis ; volume:19 ; number:1 ; day:23 ; month:1 ; year:2017 ; pages:1 ; date:12.2017
Arthritis Research & Therapy ; 19, Heft 1 (23.1.2017), 1, 12.2017
- Keyword
-
Orthopädie
- Creator
-
Sellam, Jérémie
- Contributor
-
Rivière, Elodie
Courties, Alice
Rouzaire, Paul-Olivier
Tolusso, Barbara
Vital, Edward M.
Emery, Paul
Ferracioli, Gianfranco
Soubrier, Martin
Ly, Bineta
Chavez, Houria Hendel
Taoufik, Yassine
Dougados, Maxime
Mariette, Xavier
SpringerLink (Online service)
- DOI
-
10.1186/s13075-017-1221-4
- URN
-
urn:nbn:de:1111-20170218338
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sellam, Jérémie
- Rivière, Elodie
- Courties, Alice
- Rouzaire, Paul-Olivier
- Tolusso, Barbara
- Vital, Edward M.
- Emery, Paul
- Ferracioli, Gianfranco
- Soubrier, Martin
- Ly, Bineta
- Chavez, Houria Hendel
- Taoufik, Yassine
- Dougados, Maxime
- Mariette, Xavier
- SpringerLink (Online service)
Other Objects (12)
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Erratum to: Predicting progression of Alzheimer's disease
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
A rheumatoid factor paradox: inhibition of rituximab effector function
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
Erratum to
Erratum to: Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Erratum to: Predicting progression of Alzheimer's disease
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
A rheumatoid factor paradox: inhibition of rituximab effector function
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
Erratum to
Erratum to: Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Erratum to: Predicting progression of Alzheimer's disease
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
A rheumatoid factor paradox: inhibition of rituximab effector function
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
Erratum to
Erratum to: Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis